Literature DB >> 15516441

Trophoblastic tissue spread to the sigmoid colon after uterine perforation.

Ishai Levin1, Dan Grisaru, David Pauzner, Benny Almog.   

Abstract

BACKGROUND: Trophoblastic tissue spread following uterine perforation during dilation and curettage is rare. We present a case of trophoblastic spread to the sigmoid colon following uterine perforation, which was treated by surgical removal of the implants and intramuscular administration of methotrexate. CASE: A woman presented 3 weeks after curettage for a blighted ovum. Laparotomy performed for suspected intra-abdominal bleeding revealed bleeding trophoblastic implants in a perforation tract and the anterior uterine wall and on the appendix epiploica of the sigmoid colon. The implants were surgically removed and methotrexate was administered for persistently high beta-hCG levels. The patient fully recovered.
CONCLUSION: Extrauterine trophoblastic implants should be considered in women evaluated for abdominal pain whose pregnancy test is positive after uterine perforation. Conservative treatment with methotrexate in nonacute patients may be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516441     DOI: 10.1097/01.AOG.0000128113.82312.34

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Peritoneal metastases from mucinous endocervical adenocarcinoma.

Authors:  Paul H Sugarbaker; Ashvin Kumar Rangole; Norman John Carr
Journal:  Gynecol Oncol Rep       Date:  2014-12-06

2.  Persistent low-level elevation of serum human chorionic gonadotropin after termination of pregnancy: a rare case of peritoneal trophoblastic implant.

Authors:  Hye Won Seo; Min Jin Jeong; Jung Namkung; Chan Joo Kim; Ji Young Kwon
Journal:  Obstet Gynecol Sci       Date:  2017-10-24

3.  Is Cytoreductive Surgery Possible in Cervical Cancer Peritoneal Carcinomatosis?

Authors:  Ozgul Duzgun; Murat Kalin
Journal:  Clin Med Insights Oncol       Date:  2021-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.